Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of the study is to establish a safe dose of AZD8055 in patients with mild or
moderate liver disease by providing information on any potential side effects this drug may
cause and collecting data about how hepatocellular carcinoma responds to the drug.